Published on September 14, 2009 at 3:25 AM
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multiple sclerosis (MS) patients taking TYSABRI- (natalizumab) experienced an improvement in both their physical function and psychological well-being. Findings from the study, which was performed in conjunction with HealthCore Inc., a health-outcomes research company, are the first attempt to assess patient experiences with TYSABRI in usual-care settings. The data, presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), shows patients report TYSABRI has an impact in improving their overall quality of life.
"The symptoms that an MS patient deals with on a daily basis result in significant psychological and physical effects that can adversely impact their quality of life," said William Stuart, M.D., medical director of the Multiple Sclerosis Center of Atlanta. "In a previous pivotal trial, TYSABRI not only showed a reduction in relapse rates and disability progression, but also improved quality of life. Results from this observational study further demonstrate the impact of TYSABRI on improving MS patients' well-being as reported by patients who live with this disease every day."
http://www.biogenidec.com/
5147cd69-3b37-4bdb-aef5-ed9ec4f23941|1|4.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Anxiety, Arthritis, Biotechnology, Brain, Depression, Headache, Hypersensitivity, Lymphoma, Mental Health, Multiple Sclerosis, Neurology, Neuroscience, Rheumatoid Arthritis